The daily ally for your patients with vitamin d deficiency

The first and only 2,000 IU prescribed daily dose of vitamin D supplement available in Canada for the treatment and prevention of vitamin D deficiency1.

You must be a qualified health care practitioner (HCP) to continue. I attest that I am a HCP

x To request samples

To receive the latest news on Vitamin D or Luxa-D 2,000 IU

      About vitamin D deficiency

      Signs and symptoms of vitamin D deficiency are not obvious. They may include fatigue, bone pain, muscle weakness, muscle aches or muscle cramps, mood changes and depression.

      Scientific literature supports that vitamin D may play a role in reducing the risk of:

      Osteoporosis and low bone density5

      Chronic and inflammatory diseases: Diabetes and Multiple Sclerosis6,7

      Developing certain auto-immune diseases: Allergies & Asthma6,7

      Developing certain types of cancers6,7,9,10

      Developing certain infections6,8

      Developing severe respiratory tract infection like COVID-19 contagion14,15,16,17,18,19,20

      Cardiovascular complications7,11,12

      Suffering from neurocognitive disorders7,12,13

      The right dosage for the right patient

      Did you know that 2/3 of Canadians are under the optimal serum level of 75 nmol/L 25(OH) – Vitamin D?

      A vitamin D intake of 2,000 IU/day is needed to achieve optimal of 75nmol/L with 25(OH)D mean serum level in 85-90% of adults2.

      Prevent vitamin D deficiency in your patients who need it the most.

      Do you see these patients in your practice? They may be in need of a greater dosage.

      Aged 50 and over21


      Pregnant/ breastfeeding26,27


      Luxa-D 2000 IU: to ensure optimal intake in your patients with vitamin D insufficiency1,4

      A Canadian study showed that the dose required to reach a lower target of 50 nmol/L should be:3*

      1885 IU for individuals with a normal weight

      2802 IU for overweight individuals

      6235 IU for obese individuals

      Osteoporosis Canada recommends that all Canadian adults take a vitamin D supplement (specifically, vitamin D3 or cholecalciferol) year-round and not just seasonnaly.28

      Advantages of Luxa-D 2000IU

      Luxa-D 2000 IU: to ensure optimal intake in your patients with vitamin D insufficiency1,4

      Why choosing Luxa-D 2000 IU over other vitamin D brands and dosages?

      • The only Rx vitamin D 2,000 IU marketed in Canada
      • Covered by RAMQ, most private insurance plans and NIHB plan
      • 2,000 IU for the same price as 1,000 IU
      • Made in Canada and marketed by a Canadian company
      The only vitamin D 2000 UI in Canada
      Reimbursed by most private insurances
      Double the amount for the same price
      Drug manufactured in Canada

      Is LUXA-D the suitable choice for your patient?

      Indications and clinical use

      LUXA-D is indicated for the:

      • treatment and prevention of vitamin D deficiency;
      • management and prevention of primary and corticosteroid-induced osteoporosis, in conjunction with calcium;
      • treatment of refractory rickets (vitamin D resistant rickets);
      • treatment of familial hypophosphatemia;
      • treatment of hypoparathyroidism.


      LUXA-D should not be prescribed to patients with:

      • hypercalcemia and/or hypercalciuria;
      • nephrolithiasis (renal calculi);
      • severe renal impairment;
      • malabsorption syndrome;
      • abnormal sensitivity to the toxic effects of Vitamin D;
      • hypervitaminosis D.

      Relevant warnings and precautions:

      • Administration of excessive doses may lead to hypervitaminosis D
      • Interindividual variation in dose may lead to chronic toxicity
      • Periodic monitoring of serum calcium, phosphate, magnesium, and alkaline phosphatase is recommended
      • Avoid use in excess of recommended dietary allowance in pregnant and nursing women

      For more information:

      Please consult the prescribing information at for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

      To reach a Medical information Agent for more information on the product, please contact us at or 1-866-399-9091 #2.

      To reach a Sales Representative, please contact us at:

      1. LUXA-D® Product Monograph. Orimed Pharma Inc., May 30, 2019.

      2. Bosomworth NJ. Mitigating epidemic vitamin D deficiency: the agony of evidence. Can Fam Physician. 2011 Jan;57(1):16-20, e1-6.

      3. Veugelers PJ et al. Optimal Vitamin D Supplementation Doses that Minimize the Risk for Both Low and High Serum 25-Hydroxyvitamin D Concentrations in the General Population. Nutrients. 2015;7(12):10189-10208.

      4. Bosomworth NJ. Mitigating epidemic vitamin D deficiency: the agony of evidence. Can Fam Physician. 2011 Jan;57(1):16-20, e1-6.


      6. Holick MF. Rheum Dis Clin North Am. 2012;38(1):141-160.

      7. Hossein-nezhad A, Holick MF. Mayo Clinic proceedings Mayo Clinic. 2013;88(7):720-755. doi:10.1016lj.mayocp.2013.05. 011.

      8. Rech, M.A.; Fleming, J.N.; Moore, C.L. Exp. Clln. Transplant. 2014, 12, 95-10011.Colston K, et al. Endocrlnology. 1981 Mar; 108(3):1083-6.

      9. Cross HS, Barels P, Hofer H, Blschof MG, et al. Sterolds. 2001 Mar-May; 66(3-5):287-92.

      10. Feldman D, Zhao XV, Krlshnan AV. Endocrlnology. 2000Jan;141(1):5-9.

      11. Messa, P.; et al. Am. J. Cardlovasc. Drugs 2014, 14, 114.

      12. De Metrio M., et al. Medicine (Baltimore). 2015 May;94(19):e857.

      13. Matthew R. Durk, et al. The Journal ofNeuroscience, May 21, 2014 • 34(21):7091-7101 • 70


      15. Ilie et al Aging Clinical and Experimental Research May 6, 202

      16. Daneshkhah et al Northwestern University May 2020

      17. Abu-Amer et al 1993 Cell Immunol 151: 356-368

      18. Helming et al Blood 106: 4351-4358

      19. Kuka et al 2006 Curr Opin Pharmacol 6: 271-276

      20. Cui et al 2019 Redox Biol 26: 101295

      21. Holick MF et al. Vitamin D Deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81.

      22. Harris SS. Vitamin D and African Americans. J Nutr. 2006 Apr;136(4):1126-1129.

      23. Bodnar LM et al. High Prevalence of Vitamin D Insufficiency in Black and White Pregnant Women Residing in the Northern United States and Their Neonates. J Nutr. 2007 Feb;137(2):447-452.

      24. Kremer R et al. Vitamin D Status and Its Relationship to Body Fat, Final Height, and Peak Bone Mass in Young Women. J Clin Endocrinol Metab. 2009 Jan; 94(1):67-73.

      25. Cheng S et al. Adiposity, Cardiometabolic Risk, and Vitamin D Status: The Framingham Heart Study. Diabetes. 2010 Jan;59:242-248.

      26. Hollis BW et al. Assessment of dietary vitamin D requirements during pregnancy and lactation. Am J Clin Nutr. 2004 May;79(5):717-26.

      27. Hollis BW et al. Maternal Versus Infant Vitamin D Supplementation During Lactation: A Randomized Controlled Trial. Pediatrics. 2015 Oct;136(4):625-34.

      28: Osteoporosis Canada.


      * Based on a total of 13,987 recordings of lifestyle, medical history and biometric measures (height, weight, waist circumference, blood pressure) as well as 25(OH)D concentrations from 18 to 70 year-old healthy Canadian participants in a preventive health program provided by the Canada based Pure North S’Energy Foundation.